New pneumococcal vaccine from Serum Institute of India achieves WHO prequalification

Milestones :: Perspectives :: Research

 

New pneumococcal vaccine from Serum Institute of India achieves WHO prequalification
December 19, 2019 by Lauren Newhouse
This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries
Pune, India and Seattle, United States, December 19, 2019—PNEUMOSIL®, a vaccine against a leading cause of deadly childhood pneumonia—the pneumococcus bacterium—has achieved prequalification by the World Health Organization (WHO). Developed though a collaboration spanning over a decade between Serum Institute of India, Pvt., Ltd. (SIIPL) and PATH and with funding from the Bill & Melinda Gates Foundation, the vaccine is expected to provide protection for children on par with other pneumococcal conjugate vaccines at a price that is more affordable for low- and middle-income countries…